Replies to post #311328 on Amarin Corp Plc (AMRN)

[Meowza]

risk would be gV shows statistically similar results

That risk is already assumed. A GV v V (say that 3 times fast) study showing NSS difference would change little if anything. And there's multiple plausible MOA's to potentially cause a difference.

[sts66]

A head to head comparison trial could and would measure other biomarkers AMRN has measured before, like Lp-PLA2, hs-CRP, Apo-b, a few others that may be the actual MOA for V in reducing CVD risk - they would indirectly be showing GV is not equivalent, not based on effect on TGs but other stuff.